Zolmitriptan Spray
NDC Package 45802-711-91
Package Information
Zolmitriptan sprays is zolmitriptan Nasal Spray is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.Limitations of Use:•Only use zolmitriptan if a clear diagnosis of migraine has been established. This formulation utilizes a spray delivery system. Marketed by Padagis Israel Pharmaceuticals Ltd, this product is identified by NDC 45802-711 and is authorized under FDA application ANDA212469.
Identification & Billing
- RxCUI: 402000 - ZOLMitriptan 5 MG/ACTUAT Nasal Spray
- RxCUI: 402000 - zolmitriptan 5 MG/ACTUAT Nasal Spray
- RxCUI: 402000 - zolmitriptan 5 MG/0.1 ML Nasal Spray
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 45802 - Padagis Israel Pharmaceuticals Ltd
- 45802-711 - Zolmitriptan
- 45802-711-91 - 6 BOTTLE, SPRAY in 1 CARTON / 1 SPRAY in 1 BOTTLE, SPRAY (45802-711-00)
- 45802-711 - Zolmitriptan
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 45802-711-91 identifies a specific commercial package of 6 bottle, spray in 1 carton / 1 spray in 1 bottle, spray (45802-711-00) of Zolmitriptan, a human prescription drug labeled by Padagis Israel Pharmaceuticals Ltd. This spray is formulated for nasal use and contains zolmitriptan as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Padagis Israel Pharmaceuticals Ltd on November 16, 2021. The current certification is valid through December 31, 2026.
How is this Padagis Israel Pharmaceuticals Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 45802071191. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 6 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.